CN101069728A - Chinese medicine composition for treating chronic hepatitis B and preparing method - Google Patents
Chinese medicine composition for treating chronic hepatitis B and preparing method Download PDFInfo
- Publication number
- CN101069728A CN101069728A CNA2007101114372A CN200710111437A CN101069728A CN 101069728 A CN101069728 A CN 101069728A CN A2007101114372 A CNA2007101114372 A CN A2007101114372A CN 200710111437 A CN200710111437 A CN 200710111437A CN 101069728 A CN101069728 A CN 101069728A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- chinese medicine
- radix
- weight
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a Chinese medicine composition for effectively curing chronic hepatitis B with excellent therapeutic effect. Said Chinese medicine composition includes 19 Chinese medicinal materials of bupleurum root, ovate atractylodes root, smooth greenbrier root, peony root, salvia root, earthworm and others. Said invention also provides its preparation method and concrete steps.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, particularly relate to a kind of Chinese medicine composition for the treatment of chronic viral hepatitis B.The invention still further relates to the preparation method of this Chinese medicine composition.
Background technology
The treatment of chronic hepatitis B is a great problem of the long-term puzzlement of clinician and the world of medicine.Though the extensive clinical application research of people's recombinant interferon treatment chb once had some hope, its result is not fully up to expectations, and side effect is bigger.
Equally, domestic traditional medicine is a lot of to the primary disease report, but owing to lack complete information and long term follow-up, so even have the mistaken ideas of causing person to exist.Generally speaking, the research of chronic viral hepatitis B is problem that shoulders heavy responsibilities of medical circle with treatment always.
In view of the medicine and the method for the treatment chronic viral hepatitis B that does not have better curative effect at present, so a kind of medicine for the treatment of chronic viral hepatitis B of demand still.The inventor is through year clinical pathology surplus ten, and fluorescence immunoassay is learned research and clinical verification for many years, develops a kind of Chinese medicine composition for the treatment of chronic viral hepatitis B, thereby has finished the present invention.
Summary of the invention
Main purpose of the present invention is, weight portion is obeyed the defective that existing medicine exists, and provide a kind of Chinese medicine composition of new treatment chronic viral hepatitis B, technical problem to be solved is to make its treatment chronic viral hepatitis B more effective, more responsive and almost without any side effects, thereby is suitable for practicality more.
Another object of the present invention is to, a kind of preparation method of Chinese medicine composition of new treatment chronic viral hepatitis B is provided.
The weight ratio that effective ingredient of the present invention prepares raw material is:
Radix Bupleuri 10-20 weight portion Rhizoma Atractylodis Macrocephalae 10-30 weight portion
Rhizoma Smilacis Glabrae 10-30 weight portion Radix Paeoniae 10-30 weight portion
Radix Salviae Miltiorrhizae 10-30 weight portion Radix Puerariae 20-40 weight portion
Pheretima 10-20 weight portion Bombyx Batryticatus 10-20 weight portion
Carapax Trionycis 10-30 weight portion Carapax et Plastrum Testudinis 10-30 weight portion
Squama Manis 10-20 weight portion Herba Leonuri 10-30 weight portion
Pollen Typhae 10-20 weight portion Oletum Trogopterori 10-20 weight portion
Concha Meretricis seu Cyclinae 15-45 weight portion Pumex 15-45 weight portion
Herba Lysimachiae 15-40 weight portion Spora Lygodii 15-40 weight portion
Rhizoma Paridis 10-30.
Be preferably:
The Radix Bupleuri 15 weight portion Rhizoma Atractylodis Macrocephalaes 15 weight portions
Rhizoma Smilacis Glabrae 15 weight portion Radix Paeoniaes 30 weight portions
Radix Salviae Miltiorrhizae 30 weight portion Radix Puerariaes 30 weight portions
Pheretima 10 weight portion Bombyx Batryticatus 10 weight portions
Carapax Trionycis 20 weight portion Carapax et Plastrum Testudiniss 20 weight portions
Squama Manis 20 weight portion Herba Leonuris 15 weight portions
Pollen Typhae 15 weight portion Oletum Trogopteroris 15 weight portions
Concha Meretricis seu Cyclinae 20 weight portion Pumexs 20 weight portions
Herba Lysimachiae 20 weight portion Spora Lygodii 20 weight portions
Rhizoma Paridis 20 weight portions.
Squama Manis can replace with commensurability SHENGLONGMU among the present invention.
The effect of the main Chinese crude drug that technique scheme is mentioned is as follows:
Radix Bupleuri: separate in the harmony in the exterior, soothing the liver yang invigorating; Suppress fibroplasia, fortifying fibre protein dissolution enzymatic activity makes outgrowth collagen fiber depolymerization.
Rhizoma Smilacis Glabrae: detoxifying, removing dampness; Suppress fibroplasia, increase liver glycogen granule and dna content.(relevant) with liver cell regeneration
The Rhizoma Atractylodis Macrocephalae: the liver protecting effect inflammation-inhibiting reaction.
Radix Paeoniae: nourishing blood to suppress the hyperactive liver; Suppress the fibroblast hypertrophy, adjusting glue unit synthesizes the balance with degradation function, removes the pathologic basis of the interior microcirculation disturbance of liver, microcirculation improvement, collaborative reduction portal hypertension situation.
Radix Salviae Miltiorrhizae: blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain; Except that with the effect synergism of Radix Paeoniae, the inflammation-inhibiting activity suppresses the fibrous connective tissue hypertrophy.
Radix Puerariae: pain relieving, relieving muscles diaphoresis, rash, analgesicly promote the production of body fluid, yang invigorating antidiarrheal; The liver protecting and reduction rising portal vein pressure.
Carapax et Plastrum Testudinis, Carapax Trionycis: suppress the fibrin hypertrophy, diminishing inflammation and resolving masses is separated the stasis of blood, improves plasma protein, improves the blood flow rheology.
Squama Manis: active, the analgesic poison of holding back of subsiding a swelling; It is synthetic obviously to suppress viscose unit, and fibrin degradation improves blood clotting mechanism.
Herba Leonuri, Pollen Typhae, Oletum Trogopterori: stop the generation of microcirculation disturbance in the liver, make the cellular-restoring that has broken up normal, prevent the cytogene sudden change.
Pumex, Concha Meretricis seu Cyclinae: softening the hard mass dissipating blood stasis.
Jin Qiancao, Spora Lygodii: control cholecystitis and cholelithiasis, protection kidney.
The preparation of the effective ingredient of Chinese medicine composition of the present invention can be that raw material of Chinese medicine directly is ground into coarse powder, adds entry again and/or ethanol extraction obtains.Continue to be condensed into dry extract subsequently, mix again and/or with pharmaceutically acceptable carrier, obtain Chinese medicine composition of the present invention.
The preferred for preparation of effective ingredient of the present invention is as follows:
Crude drug is pulverized;
Earlier Carapax Trionycis, Carapax et Plastrum Testudinis, Concha Meretricis seu Cyclinae, Pumex four Chinese medicine are decocted with water 1-3 hour, add Pollen Typhae, Oletum Trogopterori, Spora Lygodii (above three flavors are decocted a drug wrapped), Radix Bupleuri, the Rhizoma Atractylodis Macrocephalae, Rhizoma Smilacis Glabrae, Radix Paeoniae, Radix Salviae Miltiorrhizae, Radix Puerariae, Pheretima, Bombyx Batryticatus, Squama Manis, Herba Leonuri, Herba Lysimachiae, Rhizoma Paridis ten five kinds of Chinese medicine then, decoct 1-3 time, each 1-3 hour, filtration, merging filtrate concentrate; Or add 70-95% ethanol again, and left standstill 24 hours, filter, filtrate recycling ethanol concentrates.
Chinese medicine composition of the present invention can be made various common formulations together with its effective ingredient and/or pharmaceutically acceptable carrier, as granule, capsule, extractum or pill etc.
Pharmaceutically acceptable carrier of the present invention includes but not limited to: excipient, as starch and derivant thereof, dextrin, calcium hydrogen phosphate, magnesium stearate, differential silica gel etc.; Disintegrating agent is as sodium carboxymethyl cellulose, hydroxypropyl cellulose etc.; Lubricant is as magnesium stearate etc.; The sugar coating material is as sucrose, Pulvis Talci, gelatin, pigment, river wax etc.; Thin film coating material is as stomach dissolution type water, pure coating material etc.
Chinese medicine composition of the present invention has heat-clearing and toxic substances removing, blood circulation invigorating efficacies, effectively treats chronic hepatitis, and does not have obvious toxic-side effects.Through clinical experiment, among the 96 routine patients, 74 examples (87%) liver function recovery in treatment 1-2 month is normal, and doing well,improving .22 example (13%) is liver power recovery in 3-7 month, and transference cure is followed up a case by regular visits to stable.
Above-mentioned explanation only is the general introduction of technical solution of the present invention, for can clearer understanding technological means of the present invention, and can be implemented according to the content of description, and for above-mentioned and other purposes, feature and advantage of the present invention can be become apparent, below especially exemplified by preferred embodiment, and conjunction with figs., be described in detail as follows.
The specific embodiment
Reach technological means and the effect that predetermined goal of the invention is taked for further setting forth the present invention, below in conjunction with preferred embodiment and clinical testing data, Chinese medicine composition of the treatment chronic viral hepatitis B that foundation the present invention is proposed and preparation method thereof, describe in detail as after.
Embodiment 1Capsule preparation of the present invention
Get the raw material of Chinese medicine of following weight:
Radix Bupleuri 20g Rhizoma Atractylodis Macrocephalae 10g
Rhizoma Smilacis Glabrae 10g Radix Paeoniae 30g
Radix Salviae Miltiorrhizae 30g Radix Puerariae 40g
Pheretima 10g Bombyx Batryticatus 10g
Carapax Trionycis 10g Carapax et Plastrum Testudinis 10g
Squama Manis 20g Herba Leonuri 30g
Pollen Typhae 20g Oletum Trogopterori 10g
Concha Meretricis seu Cyclinae 15g Pumex 15g
Herba Lysimachiae 40g Spora Lygodii 15g
Rhizoma Paridis 10g
Extract (decoction) in the water with 5 times of weight of above-mentioned raw material of Chinese medicine adding, extracted 2 hours at every turn, extract after-filtration, the medicinal residues that obtain continue water and carry, repeat 2 times, merge extractive liquid, continues and will join 70% ethanol in the extracting solution, make determining alcohol reach 60%, left standstill 24 hours, and filtered, concentrate that to obtain density be 1.20 thick paste, add starch, lactose, ethyl cellulose again, granulate, incapsulate and obtain.
Embodiment 2The preparation of granule of the present invention
Get the raw material of Chinese medicine of following weight:
Radix Bupleuri 10g Rhizoma Atractylodis Macrocephalae 30g
Rhizoma Smilacis Glabrae 30g Radix Paeoniae 10g
Radix Salviae Miltiorrhizae 10g Radix Puerariae 20g
Pheretima 20g Bombyx Batryticatus 20g
Carapax Trionycis 30g Carapax et Plastrum Testudinis 30g
Squama Manis 10g Herba Leonuri 10g
Pollen Typhae 10g Oletum Trogopterori 20g
Concha Meretricis seu Cyclinae 45g Pumex 45g
Herba Lysimachiae 15g Spora Lygodii 40g
Rhizoma Paridis 30g
Extract in the water with 10 times of weight of above-mentioned raw material of Chinese medicine adding, the each extraction 2 hours, extract after-filtration, the medicinal residues that obtain continue water to be carried, and repeats merge extractive liquid, 3 times, continuation concentrates extracting solution that to obtain density be 1.25 thick paste, add starch, lactose, ethyl cellulose again, granulate, can obtain granule of the present invention.
Embodiment 3Extractum of the present invention and pill preparation
Get the raw material of Chinese medicine of following weight:
Radix Bupleuri 15g Rhizoma Atractylodis Macrocephalae 15g
Rhizoma Smilacis Glabrae 15g Radix Paeoniae 30g
Radix Salviae Miltiorrhizae 30g Radix Puerariae 30g
Pheretima 10g Bombyx Batryticatus 10g
Carapax Trionycis 20g Carapax et Plastrum Testudinis 20g
Squama Manis 20g Herba Leonuri 15g
Pollen Typhae 15g Oletum Trogopterori 15g
Concha Meretricis seu Cyclinae 20g Pumex 20g
Herba Lysimachiae 20g Spora Lygodii 20g
Rhizoma Paridis 20g
Above-mentioned raw materials medicated powder is broken;
Earlier Carapax Trionycis, Carapax et Plastrum Testudinis, Concha Meretricis seu Cyclinae, Pumex four Chinese medicine being added 5 times of weight decoctings boiled 3 hours, add Pollen Typhae, Oletum Trogopterori, Spora Lygodii (above three flavors are decocted a drug wrapped), Radix Bupleuri, the Rhizoma Atractylodis Macrocephalae, Rhizoma Smilacis Glabrae, Radix Paeoniae, Radix Salviae Miltiorrhizae, Radix Puerariae, Pheretima, Bombyx Batryticatus, Squama Manis, Herba Leonuri, Herba Lysimachiae, Rhizoma Paridis ten five kinds of Chinese medicine then, decoct 3 times, each 1 hour, filtration, merging filtrate, concentrate, one-tenth density is that clear paste or the density of 1.02-1.05 is the thick paste of 1.20-1.25, obtains extractum of the present invention.
Continuation is made small honey pill or big honeyed pills at clear paste or thick paste adding refined honey.
Or make the watered pill with clear paste or thick paste.
Embodiment 4Capsule preparation 2 of the present invention
Get the raw material of Chinese medicine of following weight:
Radix Bupleuri 15g Rhizoma Atractylodis Macrocephalae 20g
Rhizoma Smilacis Glabrae 20g Radix Paeoniae 20g
Radix Salviae Miltiorrhizae 20g Radix Puerariae 30g
Pheretima 15g Bombyx Batryticatus 15g
Carapax Trionycis 20g Carapax et Plastrum Testudinis 20g
Squama Manis 15g Herba Leonuri 20g
Pollen Typhae 15g Oletum Trogopterori 15g
Concha Meretricis seu Cyclinae 25g Pumex 30g
Herba Lysimachiae 30g Spora Lygodii 30g
Rhizoma Paridis 20g
Crude drug is pulverized;
Earlier with Carapax Trionycis, Carapax et Plastrum Testudinis, Concha Meretricis seu Cyclinae, the decocting that the Pumex four Chinese medicine adds 10 times of weight boiled 1 hour, add Pollen Typhae then, Oletum Trogopterori, Spora Lygodii (above three flavors are decocted a drug wrapped), Radix Bupleuri, the Rhizoma Atractylodis Macrocephalae, Rhizoma Smilacis Glabrae, Radix Paeoniae, Radix Salviae Miltiorrhizae, Radix Puerariae, Pheretima, Bombyx Batryticatus, Squama Manis, Herba Leonuri, Herba Lysimachiae, Rhizoma Paridis ten five kinds of Chinese medicine, decocted 3 hours, filter, add 95% ethanol in the filtrate again, make determining alcohol reach 60%, left standstill 24 hours, filter, filtrate recycling ethanol, be condensed into the thick paste that density is 1.20-1.25, add starch again, lactose, ethyl cellulose is granulated, and dress obtains as capsule.
Embodiment 5
Get with the raw material of Chinese medicine among the embodiment 4,
Wherein replace Squama Manis with commensurability SHENGLONGMU.
Preparation method is with embodiment 4.
The test example
One, clinical data
(1), physical data
All cases are chronic viral hepatitis B acute exacerbation in the period of the 1985-1998, after the hospitalization state of an illness is recovered, continue the patient that out-patient treatment and simple outpatient service are sought medical advice.Totally 96 examples, male's 52 examples wherein, the women 44; Patient age is at 18-65 between year,＜20 years old person's 13 example; 20-40 year person's 24 examples; Age＞60 year old person's 5 examples.
(2), case is selected
1, Western medicine diagnose standard (1) etiological diagnosis: the hepatitis B virus serum mark, select positive person's 75 examples of case HbsAg (+), anti--Hbe (+) person 24 examples.The concurrent diabetes of small number of patients.
(2), clinical diagnosis:
1., the patient has in various degree weak, inappetence, body discomfort, dull pain in liver etc.Wherein 33 examples have slight jaundice, 29 examples can touch liver and (or) spleen, the slight edema of numerical example lower limb, none example has ascites.
2., lab testing: all patients' liver enzyme raises and in 5 times of upper limits of normal.33 routine jaundice patients serum's bilirubin are about 34.48 μ mol/L; A/G 67 examples are normal, 29 examples＜1: 1.5; Plasma albumin＞30g/L.Esophagus gulps down barium and does not find varicosis.
3., liver B ultrasonic result: mile abnormality 26 examples, smooth 79 examples of liver surface, smooth 17 examples are owed on the surface, and diffuse lesion person's 72 examples are arranged, splenomegaly 64 examples, P diameter＜=1.2cm 82 examples,＞1.2cm person 14 examples.
4., pathological examination: criterion is that limiting plate is complete, and portal area inflammatory infiltration person is decided to be chronic persistent hepatitis; Limiting plate destroys, and fibrous connective tissue is limited to person around lobules of liver periphery or the portal area, is decided to be slight chronic active hepatitis; Connective tissue is more gos deep into person in the lobule, is decided to be the moderate chronic active hepatitis; Fibroplasia is filled the air to big of lobule or accidental pseudolobuli former and is decided to be the severe chronic active hepatitis; Find that in a specimen＞=3 pseudolobuli persons are decided to be liver cirrhosis.It is preceding through acquisition liver living specimens such as prickle livers that 96 routine patients enter research, the standard case diagnosis: chronic persistent hepatitis 19 examples, slight chronic active hepatitis 27 examples, moderate chronic active hepatitis 32 examples, severe chronic active hepatitis 12 examples, liver cirrhosis 6 examples.
2, case is included in and exclusion standard: all ages, between year, clarifying a diagnosis was chronic persistent hepatitis B and chronic active hepatitis B at 18-65, and liver function is undesired, meets the scorchingly hot Sheng of traditional Chinese medical science epidemic disease, stagnation of phlegm-damp in middle-JIAO, syndrome of qi stagnation and blood stasis.And the asymptomatic carrier of eliminating hepatitis B, autoimmune hepatitis, drug induced hepatitis, alcoholic hepatitis and other non-hepatitis B patients; Chronic hepatitis has serious nephritis concurrently, diabetes and other reasons therapy discontinued person; Accept other treating hepatitis Bs measure person during the treatment; Do not take medicine according to the rules and can't judge the complete so that judgement person that affects the treatment of curative effect or data.
Two, Therapeutic Method
Since a lot of about the report of treatment chronic viral hepatitis B both at home and abroad, so do not establish matched group.
1, medicine: the pill of the embodiment of the invention 3 preparations, 10g/ ball.
2, method: every three months is 1 course of treatment, and per 6 months is a big course of treatment. research beginning, the patient obeys honeyed pill of the present invention, every day 20g, every day 2 times.Every 1-2 month check liver function, per 3 months check serum-virus labellings and B ultrasonic.Drug withdrawal after 2 big courses of treatment, per 6 months laboratory routine examination liver functions, hepatitis B virus serum mark and liver B ultrasonic are followed up a case by regular visits to 4 times at least, and many persons reach 8 times.
Three, therapeutic outcome
1, curative effect determinate standard: with reference to the relevant tcm syndrome curative effect determinate standard and the doctor trained in Western medicine criterion of therapeutical effect of the 6th science of nineteen ninety whole nation viral hepatitis.
The diagnostic criteria of chb:
A., hepatopathy symptom, medical history are arranged more than 1 year
B., the chronic hepatitis sign is arranged
C. there is the hepatitis B virus serology to find
D. liver function repeatedly or persistent anomaly reaches more than 1 year, liver function is damaged comprehensively
The super discovery of E.B hepatopathy chronicity sign
F. the hepatopathy reason is checked the chronicity feature is arranged
Allly meet above any three condition persons and can confirm as chronic hepatitis B.
(1) total effects: among the 96 routine patients, 74 examples (87%) liver function recovery in treatment 1-2 month is normal, doing well,improving.22 examples (13%) are liver power recovery in 3-7 month, and transference cure is followed up a case by regular visits to stable.
(2) the serum-virus labelling changes: remove 1 routine women patient and disappear at treatment HbsAg in January and HbeAg, find outside anti--HBs, other 36 examples (male 17 examples 33%, woman's 19 examples 43%), disappear in 6-12 month virus signature, negative conversion rate is the 38%. cloudy patients of commentaries on classics of this 37 example, be anti--Hbe (+) when only 3 examples (12.5%) enter research, be starkly lower than former HbeAg (+) person (47%), 16 examples are found anti--not cloudy commentaries on classics person of HBs.12 example, are anti--Hbe (+) by former HbeAg (+).
1. HbsAg is cloudy changes and relationship of sex: male's negative conversion rate is 33%, and women's negative conversion rate is 43%, both no difference of science of statistics (P＞0.05).2. the cloudy relation of changeing with the e system of HbsAg: HbeAg (+) negative conversion rate is 47% than 1.5 of anti--Hbe (+), and notable difference (P＜0.02) is arranged.3. the cloudy relation of changeing with the course of disease of HbsAg: 19 routine chronic persistent hepatitises, the slight chronic active hepatitises of 27 examples, the 32 routine moderates liver that lives, 12 routine severe chronic active hepatitises and the hardened negative conversion rate of 6 routine bars are respectively 50%, 44%, 47%, 30% and 0%.This result shows the remarkable negative conversion rate (24%) (P＜0.05) greater than the severe chb of the negative conversion rate (47%) of moderate chb HbsAg.
(3) variation of liver B ultrasonic: through the capsule of the present invention treatment of 1 big course of treatment, 14 routine portal vein diameter broadening patients all have dwindle (0.1-0.2cm) in various degree.8 examples (58%) return in second big course of treatment normally.Follow up a case by regular visits to state of an illness rehabilitation or stable through 3-5.
(4) do not find any obvious toxic-side effects in the research.
The medicinal effects of other embodiments of the invention and the foregoing description do not have obvious significant difference.
The above, it only is preferred embodiment of the present invention, be not that the present invention is done any pro forma restriction, though the present invention discloses as above with preferred embodiment, yet be not in order to limit the present invention, any those skilled in the art, in not breaking away from the technical solution of the present invention scope, when the technology contents that can utilize above-mentioned announcement is made a little change or is modified to the equivalent embodiment of equivalent variations, in every case be the content that does not break away from technical solution of the present invention, according to technical spirit of the present invention to any simple modification that above embodiment did, equivalent variations and modification all still belong in the scope of technical solution of the present invention.
Claims (7)
1, a kind of Chinese medicine composition for the treatment of chronic viral hepatitis B is characterized in that, the raw material of Chinese medicine of effective ingredient of making said composition is as follows:
Radix Bupleuri 10-20 weight portion Rhizoma Atractylodis Macrocephalae 10-30 weight portion
Rhizoma Smilacis Glabrae 10-30 weight portion Radix Paeoniae 10-30 weight portion
Radix Salviae Miltiorrhizae 10-30 weight portion Radix Puerariae 20-40 weight portion
Pheretima 10-20 weight portion Bombyx Batryticatus 10-20 weight portion
Carapax Trionycis 10-30 weight portion Carapax et Plastrum Testudinis 10-30 weight portion
Squama Manis 10-20 weight portion Herba Leonuri 10-30 weight portion
Pollen Typhae 10-20 weight portion Oletum Trogopterori 10-20 weight portion
Concha Meretricis seu Cyclinae 15-45 weight portion Pumex 15-45 weight portion
Herba Lysimachiae 15-40 weight portion Spora Lygodii 15-40 weight portion
Rhizoma Paridis 10-30 weight portion.
2, the Chinese medicine composition of treatment chronic viral hepatitis B according to claim 1 is characterized in that the wherein said raw material of Chinese medicine of making effective ingredient is as follows:
The Radix Bupleuri 15 weight portion Rhizoma Atractylodis Macrocephalaes 15 weight portions
Rhizoma Smilacis Glabrae 15 weight portion Radix Paeoniaes 30 weight portions
Radix Salviae Miltiorrhizae 30 weight portion Radix Puerariaes 30 weight portions
Pheretima 10 weight portion Bombyx Batryticatus 10 weight portions
Carapax Trionycis 20 weight portion Carapax et Plastrum Testudiniss 20 weight portions
Squama Manis 20 weight portion Herba Leonuris 15 weight portions
Pollen Typhae 15 weight portion Oletum Trogopteroris 15 weight portions
Concha Meretricis seu Cyclinae 20 weight portion Pumexs 20 weight portions
Herba Lysimachiae 20 weight portion Spora Lygodii 20 weight portions
Rhizoma Paridis 20 weight portions.
3, the Chinese medicine composition of treatment chronic viral hepatitis B according to claim 1 and 2 is characterized in that wherein said Squama Manis replaces with commensurability SHENGLONGMU.
4,, it is characterized in that it is granule, capsule, extractum or pill according to the Chinese medicine composition of arbitrary described treatment chronic viral hepatitis B in claim 1 or 2.
5, a kind of preparation method for preparing the Chinese medicine composition of treatment chronic viral hepatitis B as claimed in claim 1 is characterized in that the method for preparing effective ingredient comprises the steps:
Described raw material of Chinese medicine water extraction or water extract-alcohol precipitation are obtained.
6, the preparation method of the Chinese medicine composition of treatment chronic viral hepatitis B according to claim 5 is characterized in that the method for preparing effective ingredient comprises the steps:
Earlier Carapax Trionycis, Carapax et Plastrum Testudinis, Concha Meretricis seu Cyclinae, Pumex four Chinese medicine are decocted with water 1-3 hour, add Pollen Typhae, Oletum Trogopterori, Spora Lygodii, Radix Bupleuri, the Rhizoma Atractylodis Macrocephalae, Rhizoma Smilacis Glabrae, Radix Paeoniae, Radix Salviae Miltiorrhizae, Radix Puerariae, Pheretima, Bombyx Batryticatus, Squama Manis, Herba Leonuri, Herba Lysimachiae, Rhizoma Paridis ten five kinds of Chinese medicine then, decoct 1-3 time, each 1-3 hour, filtration, merging filtrate concentrate.
7, the preparation method of the Chinese medicine composition of treatment chronic viral hepatitis B according to claim 5 is characterized in that the method for preparing effective ingredient comprises the steps:
Earlier Carapax Trionycis, Carapax et Plastrum Testudinis, Concha Meretricis seu Cyclinae, Pumex four Chinese medicine are decocted with water 1-3 hour, add Pollen Typhae, Oletum Trogopterori, Spora Lygodii, Radix Bupleuri, the Rhizoma Atractylodis Macrocephalae, Rhizoma Smilacis Glabrae, Radix Paeoniae, Radix Salviae Miltiorrhizae, Radix Puerariae, Pheretima, Bombyx Batryticatus, Squama Manis, Herba Leonuri, Herba Lysimachiae, Rhizoma Paridis ten five kinds of Chinese medicine then, decoct 1-3 time, each 1-3 hour, filtration, merging filtrate added 70-95% ethanol again, left standstill 24 hours, filter, filtrate recycling ethanol concentrates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101114372A CN101069728A (en) | 2007-06-20 | 2007-06-20 | Chinese medicine composition for treating chronic hepatitis B and preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101114372A CN101069728A (en) | 2007-06-20 | 2007-06-20 | Chinese medicine composition for treating chronic hepatitis B and preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101069728A true CN101069728A (en) | 2007-11-14 |
Family
ID=38897247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101114372A Pending CN101069728A (en) | 2007-06-20 | 2007-06-20 | Chinese medicine composition for treating chronic hepatitis B and preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101069728A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393857A (en) * | 2013-08-19 | 2013-11-20 | 张成娟 | Drug for curing hepatitis and preparation method thereof |
| CN105853770A (en) * | 2015-01-20 | 2016-08-17 | 罗福炯 | Dietary supplement for prevention and treatment of chronic hepatitis B |
| CN113440507A (en) * | 2020-03-26 | 2021-09-28 | 复旦大学 | Application of leonurine in preparation of anti-hepatitis B virus drugs |
-
2007
- 2007-06-20 CN CNA2007101114372A patent/CN101069728A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393857A (en) * | 2013-08-19 | 2013-11-20 | 张成娟 | Drug for curing hepatitis and preparation method thereof |
| CN103393857B (en) * | 2013-08-19 | 2015-01-21 | 张成娟 | Drug for curing hepatitis and preparation method thereof |
| CN105853770A (en) * | 2015-01-20 | 2016-08-17 | 罗福炯 | Dietary supplement for prevention and treatment of chronic hepatitis B |
| CN113440507A (en) * | 2020-03-26 | 2021-09-28 | 复旦大学 | Application of leonurine in preparation of anti-hepatitis B virus drugs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103120742B (en) | Traditional Chinese medicine capsule for treating fatty liver and alcoholic liver and preparation method thereof | |
| CN1857664A (en) | Apoplexy treating preparation and its preparing process | |
| CN101708237B (en) | Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof | |
| CN102579755A (en) | Chinese medicinal formula for treating chronic renal failure | |
| CN1112836A (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN101069728A (en) | Chinese medicine composition for treating chronic hepatitis B and preparing method | |
| CN101361821B (en) | Medicine combination for treating diabetic peripheral neuropathy and preparation method thereof | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN102885928B (en) | Chinese medicinal injection for treating jaundice and preparation method thereof | |
| CN101073660A (en) | Chinese-medicinal composition for treating chronic hepatitis B and its production | |
| CN104288594A (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency syndrome of chronic kidney disease and preparation method of traditional Chinese medicine preparation | |
| CN103142844A (en) | Pharmaceutical composition for treating diabetic nephropathy | |
| CN103239562B (en) | Traditional Kazak medicament composition for treating diabetes mellitus and preparation method of traditional Kazak medicament composition | |
| CN1269513C (en) | Medicament for treating hepatic fibrosis and hepatic cirrhosis | |
| CN1083721C (en) | Compound Chinese herb medicine for curing fibrosis of liver and hepatocirrhosis and its preparation method | |
| CN102357172B (en) | Traditional Chinese medicine composition for curing early chronic renal insufficiency | |
| CN102091165A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN112451618A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy | |
| CN102335399B (en) | Chinese medicinal composition for treating liver cirrhosis in early stage | |
| CN115137785B (en) | Membranous kidney prescription for treating idiopathic membranous nephropathy | |
| CN116585412B (en) | Traditional Chinese medicine composition for treating chronic nephritis and preparation method thereof | |
| CN105288410A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application of traditional Chinese medicine composition | |
| CN103251697A (en) | Medicinal composition for treating diabetic peripheral neuropathy, and preparation method thereof | |
| CN100406054C (en) | Chinese-medicinal preparation for treating hypertension and preventing lesion | |
| CN101543612A (en) | Chinese medicament for treating malignant lymphoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20071114 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |